Isoleucine.

Leucine, isoleucine and valine share the BCAT transaminase and the BCKDH complex, so they are metabolised by one pathway and compete for it. A large single-BCAA dose shifts the balance of the other two.

Valine and isoleucine are both handled by the shared BCKDH complex and compete for the same amino acid transporters. This is why branched-chain amino acids are dosed as a set rather than singly.

Branched-chain aminotransferase uses pyridoxal phosphate to move the amino group off isoleucine in the first catabolic step. Without B6 the pathway stalls at the start.

The branched-chain ketoacid dehydrogenase complex needs thiamine pyrophosphate for its decarboxylating subunit. Thiamine status therefore governs isoleucine breakdown.

The E3 subunit of BCKDH and the downstream acyl-CoA dehydrogenases all use FAD derived from riboflavin. It is one of the four vitamin cofactors the complex requires.

Isoleucine catabolism runs through CoA thioesters, and coenzyme A is built from pantothenic acid. Every acyl intermediate in the pathway needs it.

Isoleucine breakdown yields propionyl-CoA, and propionyl-CoA carboxylase is biotin-dependent. Biotin is what lets that intermediate move onward.

The propionyl-CoA from isoleucine passes through methylmalonyl-CoA, whose mutase needs adenosylcobalamin. B12 status shows up directly in how this intermediate clears.

The amino group removed from isoleucine in muscle is passed to glutamate and exported largely as glutamine and alanine. The two amino acids sit on either side of the same nitrogen transfer.

Branched-chain amino acids and tryptophan compete for the LAT1 large neutral amino acid carrier at the blood-brain barrier. A branched-chain dose lowers how much tryptophan crosses.

Tyrosine uses the same LAT1 carrier that branched-chain amino acids saturate, so entry into brain tissue is competitive. Timing them apart is the usual arrangement.

The branched-chain alpha-ketoacid dehydrogenase complex that carries out the committed step of isoleucine catabolism is built on the same E1-E2-E3 architecture as pyruvate dehydrogenase, with a lipoyl arm on the E2 core. Lipoic acid is that arm. Without it the complex cannot shuttle the acyl group to coenzyme A.

NAD is the terminal electron acceptor for the branched-chain ketoacid dehydrogenase step and for the dehydrogenases further down the isoleucine route. Vitamin B3 supplies that NAD pool. This is a cofactor requirement of the pathway rather than a supplementation finding.

Isoleucine breakdown yields propionyl-CoA, and carnitine acyltransferases convert accumulating short-chain acyl-CoA species to their carnitine esters so they can leave the mitochondrion. That is how the free coenzyme A pool is protected when branched-chain amino acid flux is high. The relationship is well characterised in acyl-CoA handling.

Threonine and isoleucine both terminate in propionyl-CoA, and in bacterial and plant biosynthesis threonine is the direct precursor from which isoleucine is built. In animal feeding work the two also interact at the level of dietary amino acid balance, where one in large excess can depress use of the other. The co-occurrence index flags this pair as antagonistic in part of the literature, which reflects that balance effect rather than a chemical incompatibility.

Methionine catabolism converges on propionyl-CoA, the same intermediate isoleucine produces, and both then run through propionyl-CoA carboxylase and methylmalonyl-CoA mutase to reach succinyl-CoA. They therefore share a bottleneck and share the biotin and B12 cofactor demand at it. This is pathway architecture, not a tested pairing.

Isoleucine and phenylalanine are both large neutral amino acids carried across membranes, including the blood-brain barrier, by the LAT1 transporter. A large dose of one lowers transport of the other for as long as plasma levels stay skewed. This is the standard explanation for why single free amino acids are usually given away from mixed protein.

Histidine is also an LAT1 substrate and competes with isoleucine for the same carrier sites. The competition is concentration-dependent and transient. It matters for timing of isolated amino acid doses rather than for protein-containing meals.

Whey is naturally rich in all three branched-chain amino acids, so it supplies isoleucine alongside the full set of essential amino acids needed for muscle protein synthesis. Isolated isoleucine cannot support protein synthesis on its own, since the ribosome needs every essential residue present. Pairing the two is why free BCAAs are usually positioned around a whole-protein base.

Casein delivers the same complete essential amino acid set as whey with a slower gastric emptying and appearance profile. As a background protein source it keeps the other essential residues available while free isoleucine peaks and clears quickly. The reasoning is nutritional rather than a measured combination effect.

HMB is a downstream metabolite of leucine, isoleucine's closest structural relative, and the two sit in the same branched-chain metabolic family that feeds muscle protein regulation. Formulas often carry both for that reason. Whether the combination adds anything beyond either alone has not been separated out in trials.

Creatine and branched-chain amino acids act on entirely different systems, phosphocreatine energy buffering and amino acid supply for protein synthesis, and are combined in training formulas on that non-overlapping logic. The pairing is convention rather than a demonstrated interaction. Read it as formulation practice.

The E3 subunit shared by the branched-chain ketoacid dehydrogenase complex is a flavoprotein, and the acyl-CoA dehydrogenase that acts on the isoleucine-derived intermediate is FAD-dependent. Riboflavin supplies both flavin cofactors. This is a requirement of the pathway.